About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

796.80 +20.36 (+2.62%)
Streaming Delayed Price Updated: 2:47 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Time to Buy These 3 Cheap Stocks?
Via The Motley Fool
Should You Invest $1,000 in Eli Lilly today?
Via The Motley Fool
Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics
China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma. 
Via Stocktwits
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Underrated Reason to Buy This Market-Beating Stock
Via The Motley Fool
Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027
Via The Motley Fool
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
Via Benzinga
The 9 Best Stocks to Buy Now in June (2025)
Via The Motley Fool
Topics Artificial Intelligence
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases. 
Via Benzinga
Better Dividend ETF to Buy Now: Schwab U.S. Dividend Equity ETF or Vanguard Dividend Appreciation ETF?
Dive deep into two popular dividend ETFs to determine which is right for your portfolio. 
Via The Motley Fool
Topics ETFs Stocks
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europe
The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform. 
Via Investor's Business Daily
Topics ETFs
Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In June
Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly. 
Via Benzinga
Topics Stocks
P/E Ratio Insights for Eli Lilly
Via Benzinga
Eli Lilly Rises 1.5% After Key Trading Signal
A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%. 
Via Benzinga
Could Viking Therapeutics Become the Next Eli Lilly?
Via The Motley Fool
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Via PR Leap
Top S&P500 movers in Friday's session
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study. 
Via Investor's Business Daily
2 Top Stocks to Buy With Less Than $100
Via The Motley Fool
3 American Growth Giants to Invest in for the Long Haul
Via The Motley Fool
Topics Artificial Intelligence World Trade
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
Looking for a Blend of Growth and Dividend Stocks Amid Market Uncertainty? Consider This Low-Cost Vanguard ETF.
Via The Motley Fool
Topics Artificial Intelligence ETFs
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator. 
Via MarketBeat
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels. 
Via The Motley Fool
Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound?
Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher. 
Via Benzinga
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives
Eli Lilly to acquire SiteOne Therapeutics in a deal worth up to $1 billion, advancing the development of a potential non-opioid treatment for chronic pain. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.